A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients

Kidney International, Supplement

Volumn 63, Issue 85, 2003, Pages

  D'Haese, Patrick C ^b   Spasovski, Goce B ^b   Sikole, Aleksander ^b   Hutchison, Alastair ^b   Freemont, Tony J ^b   Sulkova, Sylvie ^b   Swanepoel, Charles ^b   Pejanovic, Svetlana ^b   Djukanovic, Llubica ^b   Balducci, Alessandro ^b   Coen, Giorgio ^b   Sulowicz, Waldysaw ^b   Ferreira, Anibal ^b   Torres, Armando ^b   Curic, Slobodan ^b   Popovic, Milan ^b   Dimkovic, Nada ^b   De Broe, Marc E ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

Bone histomorphometry; Chronic renal failure; Open label study; Osteodystrophy; Phosphate binder

Indexed keywords

CALCIUM CARBONATE; LANTHANUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; UNCLASSIFIED DRUG;

ADULT; BONE BIOPSY; BONE TURNOVER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DRUG ABSORPTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MULTICENTER STUDY; OSTEOMALACIA; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL OSTEODYSTROPHY; SIDE EFFECT;

EID: 0038187803     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.63.s85.18.x     Document Type: Conference Paper

References (20)

1. DELMEZ JA, SLATOPOLSKY E: Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19:303-317, 1999
2. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35(6):1226-1237.
3. GOODMAN WG: Bone disease and aluminium: Pathogenic considerations. Am J Kidney Dis 6:330-335, 1985
4. DE BROE ME, COBURN JW, editors: Aluminum and Renal Failure. Dordrecht, Kluwer Acad Publ, 1990, pp 99-375
5. GOODMAN WG, GOLDIN J, KUIZON BD: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
6. LEVIN NW, HOENICH NA: Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Nephrol Hypert 10:563-568, 2001
7. KURZ P, MONIER-FAUGERE MC, BOGNAR B, et al: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855-861, 1994
8. WILKES BM, REINER D, KERN M, et al: Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenGel) in dialysis patients. Clin Nephrol 50(6):381-386, 1998
9. CHERTOW GM, BURKE SK, RAGGI P, et al: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
10. HERGESELL O, RITZ E: Phosphate binders in uremia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant 17:14-17, 2002
11. FOURNIER A, BARSOUM J, FICKL R, et al: Sevelamer, Ca X P product and vitamin D. Nephrol Dial Transplant 16:429-436, 2001
12. HERGESELL O, RITZ E: Phosphate binders on iron basis: A new perspective. Kidney Int 56(Suppl 73):42-45, 1999
13. BULMAN RA: Europium and other lanthanides, in Handbook on metals in clinical and analytical chemistry, edited by Seiler HG, Sigel A, Sigel H, New York, Marcel Dekker, Inc., 1994, pp 351-363
14. YOKEL RA, MCNAMARA PJ: Aluminium toxicokinetics: An updated MiniReview. Pharmacol Toxicol 88(4):159-167, 2001
15. CUETO-MANZO AM, KONEL S, HUTCHINSON AJ, et al: Bone loss in long term renal transplanatation: Histopathology and densitometry analysis. Kidney Int 55:2021-2029, 1999
16. MALLUCHE HH, MAWAD H: Management of hyperphosphataemia of chronic kidney disease: Lessons from the past and future directions. Nephrol Dial Transplant 17:1170-1175, 2002
17. HUTCHISON AJ: Calcitriol, lanthanum carbonate and other phosphate binders in the management of renal osteodystrophy. Perit Dial Int 19(Suppl 2):408-412, 1999
18. 26Al and accelerator mass spectrometry. Clin Nephrol 40(4):244-248, 1993
19. D'HAESE PC, COUTTENYE M-M, GOODMAN WG, et al: Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 10:1874-1884, 1995
20. COBURN JW, NORRIS KC, NEBEKER HG: Osteomalacia and bone disease arising from aluminium. Sem Nephrol 6(1):68-89, 1986